Innate Pharma SA (IPHA) said Monday it has dosed its first patient in a phase 1 study to investigate the safety and tolerability of IPH4502, an antibody-drug conjugate for the potential treatment of patients with advanced solid tumors known to express Nectin-4.
IPH4502 is designed to target Nectin-4, a cell adhesion molecule in several types of solid tumors, including urothelial carcinoma, breast cancer, non-small cell lung cancer, and gastrointestinal cancer, the company said.
The study plans to enroll about 105 patients, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments